Skip to main content

Table 1 Demographic and clinical characteristics

From: C-reactive protein or procalcitonin combined with rhinorrhea for discrimination of viral from bacterial infections in hospitalized adults in non-intensive care units with lower respiratory tract infections

Variable

Virus (N = 145)

Bacteria (N = 64)

p value

Age (years)

64 (48, 78)

64(54, 76)

0.8319

Male (%)

78 (54)

42 (66)

0.1820

Observation

   

BMI (kg/cm2)

23.4 (20.4, 25.9)

22.2 (18.6, 26.0)

0.3168

Respiratory frequency (bpm)

20 (20, 22)

20 (20, 21)

0.6199

Heart rate (bpm)

90 (80, 100)

95 (80, 102)

0.2724

Fever (%)

105 (72.4)

39 (60.9)

0.0985

Cough (%)

142 (97.9)

63 (98.4)

0.8018

Chest pain (%)

36 (24.8)

15 (23.4)

0.8293

Headache (%)

53 (36.6)

12 (18.8)

0.0104

Rhinorrhea (%)

80 (55.2)

13 (20.3)

 < .0001

Final diagnosis (%)

  

 < .0001

 CAP

87/145 (60.0)

23/64 (35.9)

 

 AECOPD

38/145 (26.2)

21/64 (32.8)

 

 AE of bronchiectasis

20/145 (13.7)

20/64 (31.3)

 

Dyspnea (%)

110 (75.9)

53 (82.8)

0.2636

Diarrhea (%)

25 (17.2)

6 (9.4)

0.1403

Comorbidity (%)

   

Cardiovascular disease

66 (45.5)

32 (50.0)

0.5495

Diabetes

32 (22.1)

19 (29.7)

0.2372

Renal disease

9 (6.2)

3 (4.7)

0.6577

Liver disease

2 (1.4)

1 (1.6)

0.9189

Cancer

9 (6.2)

4 (6.3)

0.2493

Current smoker

24 (16.6)

10 (15.6)

0.8671

Influenza vaccine(< 1 year)

14 (9.7)

11 (17.2)

0.1219

Laboratory test

   

White blood cell count(*109/L)

6.8 (4.8, 9.5)

7.2 (5.8, 9.7)

0.0885

Lymphocyte count(*109/L)

1.2 (0.8, 1.7)

1.3 (0.9, 1.8)

0.1523

Neutrophil count(*109/L)

4.4 (2.7, 6.7)

4.9 (4.0, 7.3)

0.0087

Procalcitonin(ng/mL)

0.1 (0.1,0.2)

0.3 (0.2,0.7)

 < .0001

C-reactive protein(mg/L)

10.4 (4.0,28.0)

53.0 (23.0,96.7)

0.0001

  1. Data are presented as median (interquartile range) for continuous variables and as percent for categorical variables
  2. Categorical variables were compared using χ2 tests, and continuous variables were compared using Wilcoxon rank-sum test or Student’s t test
  3. AE acute exacerbation; AECOPD acute exacerbation of chronic obstructive pulmonary disease; CAP community-acquired pneumonia